B7 homolog 3 in pancreatic cancer  

作　　者：Dijana Perovic Marija Dusanovic Pjevic Vladimir Perovic Milka Grk Milica Rasic Maja Milickovic Tanja Mijovic Petar Rasic 

机构地区：[1]Institute of Human Genetics,Faculty of Medicine,University of Belgrade,Belgrade 11000,Serbia [2]Institute of Microbiology and Immunology,Faculty of Medicine,University of Belgrade,Belgrade 11000,Serbia [3]Department of Abdominal Surgery,Mother and Child Health Care Institute of Serbia“Dr.Vukan Cupic”,Belgrade 11000,Serbia [4]Faculty of Medicine,University of Belgrade,Belgrade 11000,Serbia

出　　处：《World Journal of Gastroenterology》2024年第31期3654-3667,共14页世界胃肠病学杂志（英文版）

摘　　要：Despite advances in cancer treatment,pancreatic cancer(PC)remains a disease with high mortality rates and poor survival outcomes.The B7 homolog 3(B7-H3)checkpoint molecule is overexpressed among many malignant tumors,including PC,with low or absent expression in healthy tissues.By modulating various immunological and nonimmunological molecular mechanisms,B7-H3 may influence the progression of PC.However,the impact of B7-H3 on the survival of patients with PC remains a subject of debate.Still,most available scientific data recognize this molecule as a suppressive factor to antitumor immunity in PC.Furthermore,it has been demonstrated that B7-H3 stimulates the migration,invasion,and metastasis of PC cells,and enhances resistance to chemotherapy.In preclinical models of PC,B7-H3-targeting monoclonal antibodies have exerted profound antitumor effects by increasing natural killer cell-mediated antibodydependent cellular cytotoxicity and delivering radioisotopes and cytotoxic drugs to the tumor site.Finally,PC treatment with B7-H3-targeting antibody-drug conjugates and chimeric antigen receptor T cells is being tested in clinical studies.This review provides a comprehensive analysis of all PC-related studies in the context of B7-H3 and points to deficiencies in the current data that should be overcome by future research.

关 键 词：B7 homolog 3 Pancreatic cancer PROGNOSIS Signaling pathways IMMUNOTHERAPY 

分 类 号：R730[医药卫生—肿瘤]